India covid-19 patient reports India

DCGI sees Merck drug less effective against moderate Covid: Report

Reading now: 285
www.livemint.com

Reuters reported quoting a source with the Drug Controller General of India (DCGI). Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate Covid-19 patients, the regulator's expert committee said on Friday. "There is no significant efficacy against moderate Covid and the effective efficacy is towards mild cases," the source said on condition of anonymity due to the sensitive nature of the discussions.

The regulator and health ministry did not immediately respond to a request seeking comment. In an interim analysis of a late-stage clinical trial, molnupiravir is said to have reduced the risk of hospitalisation or death by 50%, Merck and partner Ridgeback Biotherapeutics LP announced earlier.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA